Photochemotherapy MM /09/2004. HMO; PPO; QUEST Integration June 1, 2016 Section: Medicine Place(s) of Service: Home; Office
|
|
- Iris Matthews
- 5 years ago
- Views:
Transcription
1 Photochemotherapy Policy Number: Original Effective Date: MM /09/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration June 1, 2016 Section: Medicine Place(s) of Service: Home; Office I. Photochemotherapy utilizing ultraviolet light type A (UVA) therapy is a treatment that involves exposing the patient to a photosynthesizing agent (psoralens) through oral ingestion or through bath water in conjunction with ultraviolet A light (sunlight or artificial light) for photochemotherapy of skin conditions. UVA therapy utilizing psoralens is also known as PUVA therapy. Photochemotherapy utilizing ultraviolet light type B (UVB) therapy is a treatment that involves exposing the patient to ultraviolet light type B or middle-wave ultraviolet light. It is generally used in combination with tar or anthralin. II. Criteria/Guidelines A. Photochemotherapy utilizing UVA therapy is covered (subject to Limitations/Exclusions and Administrative Guidelines) for the following diagnoses: 1. Pinta 2. Cutaneous T-cell lymphoma 3. Chronic Graft versus Host Disease refractory to standard immunosuppressive drug treatment 4. Psoriasis 5. Parapsoriasis 6. Atopic dermatitis 7. Lichen planus 8. Pityriasis rosea B. Bath water PUVA is covered if all of the following are met: 1. Patient has extensive, severe psoriasis 2. Patient had prior inability to tolerate systemic PUVA therapy and other conventional therapies. 3. Patient had no prior treatment involving carcinogenic materials (with the exception of methotrexate) including tar and UVB treatments, radiation therapy, and arsenic therapy.
2 Photochemotherapy 2 C. Photochemotherapy utilizing UVB therapy is covered (subject to Limitations/Exclusions and Administrative Guidelines) for the following diagnoses: 1. Psoriasis 2. Parapsoriasis 3. Atopic dermatitis 4. Mycosis fungoides 5. Lichen planus 6. Pityriasis rosea D. UVB units are covered for home use when a patient with a chronic condition is expected to need the unit for at least six months. The therapy should first be tried in the physician s office. Units should only be ordered for home use if therapy is tolerated and if the physician believes the patient will be compliant with regular use in the home setting. E. Photochemotherapy (with UVB plus tar or PUVA for patients with severe photoresponsive dermatoses requiring four to eight hours of care under the direct supervision of a physician is covered (subject to Limitations/Exclusions and Administrative Guidelines) under the following conditions: 1. If the therapy uses PUVA, the covered diagnoses are the same as those listed for criteria II.A. 2. If the therapy uses UVB plus tar, the covered diagnoses are the same as those listed for criteria II.C. III. Limitations A. UVA treatments should be medically supervised and are not covered in the home setting. B. Coverage of bath water PUVA is limited to 30 treatments unless improvement is documented. IV. Administrative Guidelines A. Precertification is not required. HMSA reserves the right to perform retrospective review using the above criteria to validate if services rendered met payment determination criteria. Documentation supporting the medical necessity should be legible and maintained in the patient's medical record and made available to HMSA upon request. B. For coverage for bath water PUVA, the medical record must include documentation of all of the following: 1. Prior inability to tolerate systemic PUVA therapy and other conventional therapies. 2. No prior treatment involving carcinogenic materials (with the exception of methotrexate) including tar and UVB treatments, radiation therapy, and arsenic therapy. Photochemotherapy utilizing UVA therapy codes CPT code Photochemotherapy; psoralens and ultraviolet A (PUVA) ICD-9-CM codes A67.2 Pinta, late lesions
3 Photochemotherapy 3 L20.81 L20.89 Other atopic dermatitis L40.0 L40.9 Other psoriasis L41.1 Parapsoriasis L41.9 Parapsoriasis, unspecified L42 Pityriasis rosea L43.8 Lichen planus L66.1 Lichen planopilaris C84.40 C84.49 Peripheral T-cell lymphoma D Chronic graft versus host disease CPT code Photochemotherapy utilizing UVB therapy codes Photochemotherapy; tar and ultraviolet B (Goeckerman treatment) or petrolatum and ultraviolet B ICD-10-CM codes C84.00 C84.08 Mycosis fungoides L20.81 L20.89 Other atopic dermatitis L40.0 L40.9 Other psoriasis L41.8 Parapsoriasis L41.9 Parapsoriasis, unspecified L42 Pityriasis rosea L43.8 Lichen planus L66.1 Lichen planopilaris Home Ultraviolet B Therapy HCPCS codes E0691 E0692 E0693 Ultraviolet light therapy system panel, includes bulbs/lamps, timer and eye protection; treatment area 2 square feet or less (when specified as UVB) Ultraviolet light therapy system panel, includes bulbs/lamps, timer and eye protection; 4 foot panel (when specified as UVB) Ultraviolet light therapy system panel, includes bulbs/lamps, timer and eye protection; 6 foot panel (when specified as UVB)
4 Photochemotherapy 4 E0694 Ultraviolet multidirectional light therapy system in 6 foot cabinet, includes bulbs/lamps, timer and eye protection (when specified as UVB) CPT code Photochemotherapy utilizing UVB plus tar or PUVA therapy Photochemotherapy (Goeckerman and/or PUVA) for severe photoresponsive dermatoses requiring at least four to eight hours of care under direct supervision of the physician (includes application of medication and dressings) ICD-10-CM Codes A67.2 Late lesions of pinta C84.00 C84.08 Mycosis fungoides L20.81 L20.89 Other atopic dermatitis L40.0 L40.9 Psoriasis L41.0 Pityriasis lichenoides et varioliformis acuta L41.1 Pityriasis lichenoides chronica L41.8 Other parapsoriasis L41.9 Parapsoriasis, unspecified L42 Pityriasis rosea L43.8 Other lichen planus L66.1 Lichen planopilaris C84.40-C84.49 Peripheral T-cell lymphoma D Chronic graft versus host disease V. Important Reminder The purpose of this Medical Policy is to provide a guide to coverage. This Medical Policy is not intended to dictate to providers how to practice medicine. Nothing in this Medical Policy is intended to discourage or prohibit providing other medical advice or treatment deemed appropriate by the treating physician. Benefit determinations are subject to applicable member contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. This Medical Policy has been developed through consideration of the medical necessity criteria under Hawaii s Patients Bill of Rights and Responsibilities Act (Hawaii Revised Statutes 432E-1.4), generally accepted standards of medical practice and review of medical literature and government approval
5 Photochemotherapy 5 status. HMSA has determined that services not covered under this Medical Policy will not be medically necessary under Hawaii law in most cases. If a treating physician disagrees with HMSA s determination as to medical necessity in a given case, the physician may request that HMSA reconsider the application of the medical necessity criteria to the case at issue in light of any supporting documentation. VI. References 1. Almutawa F, Thalib L, Heckman D et al. Efficacy of localized phototherapy and photodynamic therapy for psoriasis: a systematic review and meta-analysis. Photodermatol Photoimmunol Photomed. Nov 28, : [Epub ahead of print]. 2. Almutawa F, Alnomair N, Wang Y et al. Systematic review of UV-based therapy for psoriasis. Am J Clin Dermatol 2013; 14(2): BCBSA. Medical Policy Reference Manual. Policy # Psoralens with Ultraviolet A (PUVA) for Psoriasis. Archived January Bansal S, Sahoo B, Garg V. Psoralen-narrowband UVB phototherapy in treatment of vitiligo in comparison to narrowband UVB phototherapy. Photodermatol Photoimmunol Photomed Calzavara-Pinton PG, Ortel B, Honigsmann H, Zane C, De Panfilis G. Safety and effectiveness of an aggressive and individualized bath-puva regimen in the treatment of psoriasis. Dermatology 1994; 189(3): Chen X, Yang M, Cheng Y et al. Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis. Cochrane Database Syst Rev 2013; 10:CD Collins P, Rogers S. Bath water compared with oral delivery of 8-Methoxypsoralen PUVA therapy for chronic plaque psoriasis. British Journal of Dermatology 1992; 127(4): Hannuksela A, Pukkala E, Hannuksela M, Karvonen J. Cancer incidence among Finnish patients with psoriasis treated with trioxsalen bath PUVA. Journal of the American Academy of Dermatology 1996; 35(5 Pt 1): Lowe NJ, Weingarten D, Bourget T, Moy LS. PUVA therapy for psoriasis: comparison of oral and bath water delivery of 8-Methoxypsoralen. Journal of the American Academy of Dermatology 1996; 14(5 Pt 1): Menter A, Korman NJ, Elmets CA, MD, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. Journal of the American Academy of Dermatology. 62:1; Medicare Coverage Issues Manual. Section 35-66: Treatment of Psoriasis. 12. Momtaz TK, Fitzpatrick TB. Modifications of PUVA. Dermatologic Clinics 1995; 13(4): Morison WL. PUVA combination therapy. Photodermatology 1985; 2(4): National Psoriasis Foundation. PUVA viable therapy despite suspected risk. April 10, Shi Q, Li K, Fu J et al. Comparison of the 308-nm excimer laser with the 308-nm excimer lamp in the treatment of vitiligo--a randomized bilateral comparison study. Photodermatol Photoimmunol Photomed 2013; 29(1): Stern RS, Laird N. Carcinogenic risk of treatments for severe psoriasis; photochemotherapy follow-up study. Cancer 1994; 73:
6 Photochemotherapy Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (Psoralen) and ultraviolet A radiation (PUVA). New England Journal of Medicine 1997; 336(15): Wainwright NJ, MacLeod TM, Ferguson J. Bath PUVA - An investigation of the distribution of trioxsalen (TMP) and 8-Methoxypsoralen (8-MOP) in Bathwater. Photodermatology, Photoimmunology & Photomedicine 1997: 13(1-2):
Photochemotherapy MM /09/2004. HMO; PPO; QUEST Integration 08/25/2017 Section: Medicine Place(s) of Service: Home; Office
Photochemotherapy Policy Number: Original Effective Date: MM.02.015 11/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 08/25/2017 Section: Medicine Place(s) of Service:
More informationClinical Policy: Phototherapy and Photochemotherapy for Dermatological Conditions Reference Number: CP.MP. 441
Clinical Policy: Phototherapy and Photochemotherapy for Dermatological Conditions Reference Number: CP.MP. 441 Effective Date: November 2008 Last Review Date: January 2017 See Important Reminder at the
More informationPhototherapy, Photochemotherapy and Photodynamic Therapy for Dermatologic Conditions
Last Review Date: October 12, 2018 Number: MG.MM.ME.27j Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More informationPhototherapy, Photochemotherapy and Photodynamic Therapy for Dermatologic Conditions
Last Review Date: September 21, 2017 Number: MG.MM.ME.27iv2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More informationPhototherapy and Photochemotherapy Treatment (Ultraviolet A [PUVA] and B [UBV])
Origination: 09/27/07 Revised: 08/2/17 Annual Review: 11/2/17 Purpose: To provide Phototherapy and Photochemotherapy Treatment (PUVA and UBV) guidelines for the Medical Department staff to reference when
More informationCorporate Medical Policy
Corporate Medical Policy Light Therapy for Dermatologic Conditions File Name: Origination: Last CAP Review: Next CAP Review: Last Review: light_therapy_for_dermatologic_conditions 5/2012 11/2017 11/2018
More informationOriginal Policy Date
MP 2.01.07 Psoralens with Ultraviolet A (PUVA) Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed by consensus/12:2013 Return to Medical Policy
More informationA Retrospective Study on the Risk of Non-Melanoma Skin Cancer in PUVA and Narrowband UVB Treated Patients
Volume 1, Issue 3 Research Article A Retrospective Study on the Risk of Non-Melanoma Skin Cancer in PUVA and Narrowband UVB Treated Patients Darukarnphut P, Rattanakaemakorn P *, Rajatanavin N Division
More informationLight Therapy for Psoriasis Protocol Medical Benefit Effective Date Next Review Date Preauthorization Review Dates Preauthorization is required.
Protocol Light Therapy for Psoriasis (20147) Medical Benefit Effective Date: 07/01/16 Next Review Date: 03/18 Preauthorization Yes Review Dates: 03/16, 03/17 Preauthorization is required. The following
More informationCorporate Medical Policy
Corporate Medical Policy Ultraviolet Light Therapy in the Home Setting(UVB) File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ultraviolet_light_therapy_in_the_home 3/1996 11/2017 11/2018
More informationPhotodynamic Therapy for the Treatment of Actinic Keratoses and Other Skin Lesions
Photodynamic Therapy for the Treatment of Actinic Keratoses and Other Skin Lesions Policy Number: Original Effective Date: MM.02.016 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST
More informationPUVA: Shall we still use it for psoriasis in 2019?
PUVA: Shall we still use it for psoriasis in 2019? Ben Stoff MD, MA Associate Professor Emory Department of Dermatology Phototherapy: F003 March 1, 2019 DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY
More informationLaser, Light Therapy, and Cryotherapy for Acne Vulgaris Non-Pharmacologic Treatment of Rosacea
2.01.47 Light Therapy for Psoriasis Section 2.0 Medicine Subsection Effective Date October 31, 2014 Original Policy Date June 13, 2001 Next Review Date October 2015 Description Plaque psoriasis, also called
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): July 1, 2002 Most Recent Review Date (Revised): March 25, 2014 Effective Date: June 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationClinical Policy Title: Phototherapy and photochemotherapy (PUVA) for skin conditions
Clinical Policy Title: Phototherapy and photochemotherapy (PUVA) for skin conditions Clinical Policy Number: 16.02.04 Effective Date: October 1, 2015 Initial Review Date: May 20, 2015 Most Recent Review
More informationClinical Policy: Laser Therapy for Skin Conditions Reference Number: CP.MP.123 Last Review Date: 08/17
Clinical Policy: Laser Therapy for Skin Conditions Reference Number: CP.MP.123 Last Review Date: 08/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationContinuous Glucose Monitoring System
Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 4/1/2018 Section: DME Place(s)
More informationLight Therapy for Psoriasis and Eczema
Light Therapy for Psoriasis and Eczema Policy Number: 2.01.47 Last Review: 5/2018 Origination: 5/2006 Next Review: 5/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationContinuous Glucose Monitoring System
Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2016 Section: DME Place(s)
More informationContinuous Glucose Monitoring System
Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2017 Section: DME Place(s)
More informationOriginal Policy Date
MP 2.01.58 Light Therapy for Vitiligo Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Created with literature search/12:2013 Return to Medical Policy
More informationName of Policy: Phototherapy for the Treatment of Skin Disorders
Name of Policy: Phototherapy for the Treatment of Skin Disorders Policy #: 301 Latest Review Date: April 2014 Category: Medical/DME Policy Grade: B Background: As a general rule, benefits are payable under
More informationClinical Policy Title: Phototherapy and photochemotherapy for skin conditions
Clinical Policy Title: Phototherapy and photochemotherapy for skin conditions Clinical Policy Number: 16.02.04 Effective Date: October 1, 2015 Initial Review Date: May 20, 2015 Most Recent Review Date:
More informationClinical Policy Title: Phototherapy and photochemotherapy (PUVA) for skin conditions
Clinical Policy Title: Phototherapy and photochemotherapy (PUVA) for skin conditions Clinical Policy Number: 16.02.04 Effective Date: October 1, 2015 Initial Review Date: May 20, 2015 Most Recent Review
More informationNegative Pressure Wound Therapy (NPWT)
Negative Pressure Wound Therapy (NPWT) Policy Number: Original Effective Date: MM.01.005 11/19/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 01/01/2015 Section: DME Place(s) of Service:
More informationLight Therapy for Psoriasis. Description
Subject: Light Therapy for Psoriasis Page: 1 of 11 Last Review Status/Date: June 2015 Light Therapy for Psoriasis Description Light therapy for psoriasis includes both targeted phototherapy and photochemotherapy
More informationComparison of PUVA and UVB therapy in moderate plaque psoriasis. Arfan ul Bari, Nadia Iftikhar*, Simeen ber Rahman*
Comparison of PUVA and UVB therapy in moderate plaque psoriasis Arfan ul Bari et al. Arfan ul Bari, Nadia Iftikhar*, Simeen ber Rahman* Department of Dermatology, PAF Hospital, Sargodha. * Department of
More informationUse of light for the treatment of skin diseases
An Update on At-Home UVB Phototherapy At-home options increase accessibility to phototherapy, which is effective and generally safe for psoriasis management. By Joseph Bikowski, MD Use of light for the
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Ultraviolet Light Therapy for Skin Conditions Page 1 of 17 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Ultraviolet Light Therapy for Skin Conditions Professional
More informationName of Policy: Phototherapy for the Treatment of Skin Disorders
Name of Policy: Phototherapy for the Treatment of Skin Disorders Policy #: 301 Latest Review Date: December 2017 Category: Medical/DME Policy Grade: B Background: As a general rule, benefits are payable
More informationBevacizumab (Avastin)
Bevacizumab (Avastin) Policy Number: Original Effective Date: MM.04.001 09/14/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 03/01/2014 Section: Prescription Drugs Place(s) of Service:
More informationInsulin Pumps - External
Insulin Pumps - External Policy Number: Original Effective Date: MM.01.004 04/01/2011 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/20174/1/2018 Section: DME Place(s) of
More informationA.HANNUKSELA-SVAHN, B.SIGURGEIRSSON,* E.PUKKALA,² B.LINDELOÈ F,³ B.BERNE, M.HANNUKSELA, K.POIKOLAINEN AND J.KARVONEN
British Journal of Dermatology 1999; 141: 497±501. Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and
More informationRemicade (Infliximab)
Remicade (Infliximab) Policy Number: Original Effective Date: MM.04.016 11/18/2003 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 07/26/2013 Section: Prescription Drugs Place(s)
More informationPositive Airway Pressure and Oral Devices for the Treatment of Obstructive Sleep Apnea
Positive Airway Pressure and Oral Devices for the Treatment of Obstructive Sleep Apnea Policy Number: Original Effective Date: MM.01.009 11/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO
More informationPositive Airway Pressure and Oral Devices for the Treatment of Obstructive Sleep Apnea
Positive Airway Pressure and Oral Devices for the Treatment of Obstructive Sleep Apnea Policy Number: Original Effective Date: MM.01.009 11/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO;
More informationMedical Policy. MP Light Therapy for Psoriasis
Medical Policy MP 2.01.47 BCBSA Ref. Policy: 2.01.47 Last Review: 12/27/2017 Effective Date: 12/27/2017 Section: Medicine Related Policies 2.01.44 Dermatologic Applications of Photodynamic Therapy 2.01.86
More informationOxygen and Oxygen Equipment
Oxygen and Oxygen Equipment Policy Number: Original Effective Date: MM.01.008 12/01/2010 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 09/01/2013 Section: DME Place(s) of Service: Home I.
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Cosentyx, Cosentyx Sensoready) Reference Number: HIM.PA.SP29 Effective Date: 05/17 Last Review Date: Line of Business: Health Insurance Marketplace Coding Implications Revision Log See
More informationPolysomnography and Sleep Studies
Polysomnography and Sleep Studies Policy Number: Original Effective Date: MM.02.016 09/14/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/01/2014 Section: Medicine Place(s)
More informationApplied Behavior Analysis Therapy for Treatment of Autism Spectrum Disorder
Applied Behavior Analysis Therapy for Treatment of Autism Spectrum Disorder Policy Number: Original Effective Date: MM.12.022 01/01/2016 Line(s) of Business: Current Effective Date: HMO; PPO; Fed 87; FEP;
More informationBortezomib (Velcade)
Bortezomib (Velcade) Policy Number: Original Effective Date: MM.04.003 03/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 06/01/2015 Section: Prescription Drugs Place(s)
More informationPhototherapy for Psoriasis. Henry W. Lim, MD Chairman and C.S. Livingood Chair Department of Dermatology Henry Ford Hospital, Detroit, MI, USA
Phototherapy for Psoriasis Henry W. Lim, MD Chairman and C.S. Livingood Chair Department of Dermatology Henry Ford Hospital, Detroit, MI, USA Disclosure Investigator: Clinuvel Estée Lauder Ferndale Incyte
More informationApplied Behavior Analysis Therapy for Treatment of Autism Spectrum Disorder
Applied Behavior Analysis Therapy for Treatment of Autism Spectrum Disorder Policy Number: Original Effective Date: MM.12.022 01/01/2016 Line(s) of Business: Current Effective Date: HMO; PPO; Fed 87; FEP;
More informationLow-Molecular-Weight Heparin
Low-Molecular-Weight Heparin Policy Number: Original Effective Date: MM.04.019 10/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO 10/28/2011 Section: Prescription Drugs Place(s) of Service:
More informationUVB phototherapy and skin cancer risk: a review of the literature
Oxford, IJD International 0011-9059 Blackwell 45 UK Publishing Journal Ltd. Ltd, of Dermatology 2003 Review Lee, Koo, phototherapy and Berger and skin cancer risk UVB phototherapy and skin cancer risk:
More informationLung-Volume Reduction Surgery ARCHIVED
Lung-Volume Reduction Surgery ARCHIVED Policy Number: Original Effective Date: MM.06.008 04/15/2005 Line(s) of Business: Current Effective Date: PPO; HMO; QUEST 03/22/2013 Section: Surgery Place(s) of
More informationOxygen and Oxygen Equipment
Oxygen and Oxygen Equipment Policy Number: Original Effective Date: MM.01.008 12/01/2010 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 08/25/2017 Section: DME Place(s) of Service:
More informationComparison of the narrow band UVB versus systemic corticosteroids in the treatment of lichen planus: A randomized clinical trial
Received: 10.7.2011 Accepted: 5.12.2011 Original Article Comparison of the narrow band UVB versus systemic corticosteroids in the treatment of lichen planus: A randomized clinical trial Fariba Iraji, 1
More informationOriginal article Comparative study of psoralen-uvb vs. UVB-alone therapy in the treatment of psoriasis
Original article Comparative study of psoralen-uvb vs. UVB-alone therapy in the treatment of psoriasis Syed Shamsuddin, *Tahir Saeed Haroon Department of Dermatology, Bolan Medical Complex, Quetta * Department
More informationBariatric Surgery MM /11/2001. HMO; PPO; QUEST 05/01/2012 Section: Surgery Place(s) of Service: Outpatient; Inpatient
Bariatric Surgery Policy Number: Original Effective Date: MM.06.003 09/11/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 05/01/2012 Section: Surgery Place(s) of Service: Outpatient;
More informationIntensity Modulated Radiation Therapy (IMRT)
Intensity Modulated Radiation Therapy (IMRT) Policy Number: Original Effective Date: MM.05.006 03/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 03/01/2015 Section: Radiology
More informationPhysical Therapy MM /15/2003
Physical Therapy Policy Number: Original Effective Date: MM.09.005 07/15/2003 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 06/23/2017 Line(s) of Business Excluded: Federal Employee
More informationErythropoiesis Stimulating Agents (ESA)
Erythropoiesis Stimulating Agents (ESA) Policy Number: Original Effective Date: MM.04.008 04/15/2007 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 06/01/2015 Section: Prescription
More informationExtracorporeal Membrane Oxygenation (ECMO)
Extracorporeal Membrane Oxygenation (ECMO) Policy Number: Original Effective Date: MM.12.006 05/16/2006 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 11/01/2014 Section: Other/Miscellaneous
More informationProphylactic Mastectomy
Prophylactic Mastectomy Policy Number: Original Effective Date: MM.06.010 01/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO 07/22/2011 Section: Surgery Place(s) of Service: Inpatient I.
More informationNarrow-band UVB PHOTOTHERAPY for Skin Diseases
Narrow-band UVB PHOTOTHERAPY for Skin Diseases By Dr. Manal Bosseila Cairo University, Egypt HISTORICAL ASPECT In 1978: Irradiation cabin with broad band UVB tubes was introduced for psoriasis & uremic
More informationClinical Policy: Secukinumab (Cosentyx) Reference Number: ERX.SPA.165 Effective Date:
Clinical Policy: (Cosentyx) Reference Number: ERX.SPA.165 Effective Date: 10.01.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationThe utilization of phototherapy in the department of dermatology, Hospital Kuala Lumpur: A 5-year audit
ORIGINAL ARTICLE The utilization of phototherapy in the department of dermatology, Hospital Kuala Lumpur: A 5-year audit Vaani Valerie Visuvanathan, AdvMDerm 1, Min Moon Tang, AdvMDerm 2, Li Lian Tan,
More informationVelcade (bortezomib)
Velcade (bortezomib) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 03/09/2004 Current Effective Date: 05/01/2017 POLICY A. INDICATIONS The indications below
More informationTorisel (temsirolimus)
Torisel (temsirolimus) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 10/01/2015 Current Effective Date: 11/1/2017 POLICY A. INDICATIONS The indications below
More informationPsychological & Neuropsychological Test
An Independent Licensee of the Blue Cross and Blue Shield Association Psychological & Neuropsychological Test BEACON HEALTH STRATEGIES, LLC ORIGINAL EFFECTIVE DATE HAWAII LEVEL OF CARE CRITERIA 2013 CURRENT
More informationVelcade (bortezomib)
Velcade (bortezomib) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 03/09/2004 Current Effective Date: 03/01/2018 POLICY A. INDICATIONS The indications below
More informationClinical Policy: Secukinumab (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08/16 Last Review Date: 08/17
Clinical Policy: (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationStereotactic Radiosurgery and Stereotactic Body Radiation Therapy
Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2017
More informationIn former years, patients were treated with broad-band
ORIGINAL ARTICLE Efficacy of UVA1 phototherapy in 23 patients with various skin diseases S. Rombold, K. Lobisch, K. Katzer, T. C. Grazziotin, J. Ring & B. Eberlein Department of Dermatology and Allergy
More informationClinical Policy Title: Psoriasis dermatology treatment
Clinical Policy Title: Psoriasis dermatology treatment Clinical Policy Number: 16.02.06 Effective Date: October 1, 2016 Initial Review Date: September 17, 2016 Most Recent Review Date: September 21, 2017
More informationGazyva (obinutuzumab)
Gazyva (obinutuzumab) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 10/01/2015 Current Effective Date: 01/01/201807/01/2018 POLICY A. INDICATIONS The indications
More informationClinical Policy: Secukinumab (Cosentyx) Reference Number: ERX.SPA.165 Effective Date:
Clinical Policy: (Cosentyx) Reference Number: ERX.SPA.165 Effective Date: 10.01.16 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationPosterior Tibial Nerve Stimulation
Posterior Tibial Nerve Stimulation Policy Number: Original Effective Date: MM.02.025 01/01/2015 Lines of Business: Current Effective Date: HMO; PPO; QUEST Integration 02/01/2015 Section: Medicine Place(s)
More informationStereotactic Radiosurgery and Stereotactic Body Radiation Therapy
Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 03/01/2013 Section:
More informationMEDICAL POLICY SUBJECT: LIGHT AND LASER THERAPIES FOR DERMATOLOGIC CONDITIONS
MEDICAL POLICY SUBJECT: LIGHT AND LASER THERAPIES FOR PAGE: 1 OF: 9 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product (including
More informationTable 2.1. Cohort studies of treatment with methoxsalen plus UV radiation and cutaneous and extracutaneous cancers
skin Forman et al. (1989) The PUVA-48 Cooperative Study (multicentre ) Retrospective cohort of 551 psoriatic patients of both sexes treated with PUVA since 1975 in seven medical centres; cancer incidence
More informationClinical Policy: Acitretin (Soriatane) Reference Number: CP.PMN.40. Line of Business: Medicaid
Clinical Policy: (Soriatane) Reference Number: CP.PMN.40 Effective Date: 08/10 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this
More informationPerjeta (pertuzumab)
Perjeta (pertuzumab) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 10/01/2015 Current Effective Date: 01/01/201809/16/2018 POLICY A. INDICATIONS The indications
More informationSomatuline Depot (lanreotide)
Somatuline Depot (lanreotide) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 12/01/2017TBD POLICY A. INDICATIONS The indications
More informationExtracorporeal Membrane Oxygenation (ECMO)
Extracorporeal Membrane Oxygenation (ECMO) Policy Number: Original Effective Date: MM.12.006 05/16/2006 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 01/01/2017 Section: Other/Miscellaneous
More informationNational Managed Clinical Network For Phototherapy DOSIMETRY PROTOCOLS
National Managed Clinical Network For Phototherapy DOSIMETRY PROTOCOLS Photonet Dosimetry Protocols Revised March 2013 Review Date March 2015 1 MANAGED CLINICAL NETWORK SCOTLAND Photonet CONTENT DOSIMETRY
More informationNarrow band UVB (311 nm), psoralen UVB (311 nm) and PUVA therapy in the treatment of early-stage mycosis fungoides: a right left comparative study
Photodermatol Photoimmunol Photomed 2005; 21: 281 286 Blackwell Munksgaard Copyright r Blackwell Munksgaard 2005 Narrow band UVB (311 nm), psoralen UVB (311 nm) and therapy in the treatment of early-stage
More informationPHARMACY POLICY STATEMENT Ohio Medicaid
DRUG NAME BILLING CODE BENEFIT TYPE SITE OF SERVICE ALLOWED COVERAGE REQUIREMENTS LIST OF DIAGNOSES CONSIDERED NOT MEDICALLY NECESSARY PHARMACY POLICY STATEMENT Ohio Medicaid Enbrel (etanercept) Must use
More informationIntensity Modulated Radiation Therapy (IMRT)
Intensity Modulated Radiation Therapy (IMRT) Policy Number: Original Effective Date: MM.05.006 03/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO 06/24/2011 Section: Radiology Place(s) of
More informationStereotactic Radiosurgery and Stereotactic Body Radiation Therapy
Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 11/20/2015
More informationArtificial Disc Replacement, Cervical
Artificial Disc Replacement, Cervical Policy Number: Original Effective Date: MM.06.001 02/01/2010 Line(s) of Business: Current Effective Date: HMO; PPO 11/01/2011 Section: Surgery Place(s) of Service:
More informationClinical Policy: Ixekizumab (Taltz) Reference Number: CP.PHAR.257 Effective Date: Last Review Date: 05.18
Clinical Policy: (Taltz) Reference Number: CP.PHAR.257 Effective Date: 08.01.16 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationIntracellular Micronutrient Analysis
Intracellular Micronutrient Analysis Policy Number: Original Effective Date: MM.02.019 11/01/2013 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 08/28/2015 Section: Medicine Place(s)
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 2104-4 Program Prior Authorization/Medical Necessity Medication Taltz (ixekizumab) P&T Approval Date 8/2016, 5/2017, 2/2018 Effective
More informationIntracellular Micronutrient Analysis
Intracellular Micronutrient Analysis Policy Number: Original Effective Date: MM.02.019 11/01/2013 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 08/22/2014 Section: Medicine Place(s)
More informationGrowth Hormone Therapy
Growth Hormone Therapy Policy Number: Original Effective Date: MM.04.011 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/23/2014 Section: Prescription Drugs Place(s)
More informationPhotodynamic Therapy for the Treatment of Actinic Keratoses and Other Skin Lesions
Photodynamic Therapy for the Treatment of Actinic Keratoses and Other Skin Lesions Policy Number: Original Effective Date: MM.02.016 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST
More informationHome Total Parenteral Nutrition for Adults
Home Total Parenteral Nutrition for Adults Policy Number: Original Effective Date: MM.08.007 05/21/1999 Line(s) of Business: Current Effective Date: PPO, HMO, QUEST Integration 05/27/2016 Section: Home
More informationProphylactic Mastectomy
Prophylactic Mastectomy Policy Number: Original Effective Date: MM.06.010 01/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 09/01/2015 Section: Surgery Place(s) of Service:
More informationClinical Policy: Ixekizumab (Taltz) Reference Number: ERX.SPA.122 Effective Date:
Clinical Policy: (Taltz) Reference Number: ERX.SPA.122 Effective Date: 10.01.16 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationClinical Policy: Ustekinumab (Stelara) Reference Number: CP.PHAR.264
Clinical Policy: (Stelara) Reference Number: CP.PHAR.264 Effective Date: 08/16 Last Review Date: 05/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationPravit Asawanonda, MD, DSc, and Yaowalak Nateetongrungsak, MD Bangkok, Thailand
Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: A randomized, placebo-controlled study Pravit Asawanonda, MD, DSc, and
More informationEfficacy of Concomitant Use of PUVA and Methotrexate in Disease Clearance Time in Plaque Type Psoriasis
Efficacy of Concomitant Use of PUVA and Methotrexate in Disease Clearance Time in Plaque Type Psoriasis T. Shehzad ( Departments of Dermatology Naval Hospital PNS Shifa, Karachi. ) N. R. Dar ( Departments
More informationHumira (adalimumab) Line(s) of Business: HMO; PPO; QUEST Integration. Original Effective Date: 10/01/2015 Current Effective Date: 03/01/201811/01/2018
Humira (adalimumab) Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 10/01/2015 Current Effective Date: 03/01/201811/01/2018 POLICY A. INDICATIONS The indications below including
More information